Copyright © 2004, European Society of Cardiology
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
aCenter for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA, United States
bDepartment of Obstetrics and Gynecology, Clinic for Endocrinology (D217, NORD-1), University Hospital Zurich, Frauenklinikstrasse-10, CH-8051, Zurich, Switzerland
cDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
dMedical-Policlinic, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
eDepartment of Pharmacology, University of Pittsburgh, Pittsburgh, PA, United States
* Corresponding author. Department of Obstetrics and Gynecology, Clinic for Endocrinology (D217, NORD-1), University Hospital Zurich, Frauenklinikstrasse-10, CH-8051, Zurich, Switzerland. Tel.:+ 41 1 255 8608; fax: +41 1 255 4439. Email address: Raghvendra.dubey{at}usz.ch
Premenopausal women have a lower risk for cardiovascular events, and mortality due to coronary vascular disease (CVD) in premenopausal women is rare. These facts suggest that endogenous estrogens, such as estradiol, protect the cardiovascular system, and several observational studies and a few small clinical studies conducted in healthy and younger postmenopausal women support this hypothesis. In contrast, two large randomized clinical trials (RCTs), using conjugated equine estrogens and conducted in older women with established CVD or without overt CVD, failed to demonstrate protection against CVD by exogenous estrogens. These divergent findings have resulted in confusion with regard to the association between estrogen deficiency and CVD in postmenopausal women. In order to reconcile these contradictory findings, it is necessary to examine the pathophysiology associated with age-dependent changes within the vessel wall and to compare the pharmacology of different types of estrogens. Understanding age-dependent changes in vascular pathology and the pharmacology of different estrogens may facilitate the development of therapeutic strategies for hormone replacement therapy (HRT) that would be effective in delaying vascular remodeling leading to CVD following menopause. In this review we provide an overview of the impact of menopause and estrogen deficiency on vascular remodeling and emphasize the importance of timing and type of estrogen to achieve maximum benefits with regard to reducing the risk of CVD.
KEYWORDS Aging; Menopause; Hormone therapy; Estrogen; Cardiovascular disease
Time for primary review 15 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. C. Thurston, K. Sutton-Tyrrell, S. A. Everson-Rose, R. Hess, and K. A. Matthews Hot Flashes and Subclinical Cardiovascular Disease: Findings From the Study of Women's Health Across the Nation Heart Study Circulation, September 16, 2008; 118(12): 1234 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T Shuster, B. S Gostout, B. R Grossardt, and W. A Rocca Prophylactic oophorectomy in premenopausal women and long-term health Menopause Int, September 1, 2008; 14(3): 111 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mariotti Mild Hypothyroidism and Ischemic Heart Disease: Is Age the Answer? J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2969 - 2971. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Baylis Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency Physiology, June 1, 2008; 23(3): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pretorius, G. P. van Guilder, R. J. Guzman, J. M. Luther, and N. J. Brown 17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, D. Wunder, B. Imthurn, and M. Rosselli Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism Hypertension, April 1, 2008; 51(4): 1197 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pinna, A. Cignarella, P. Sanvito, V. Pelosi, and C. Bolego Prolonged Ovarian Hormone Deprivation Impairs the Protective Vascular Actions of Estrogen Receptor {alpha}Agonists Hypertension, April 1, 2008; 51(4): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Mark, R. Tatchum-Talom, D. S. Martin, and K. M. Eyster Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1969 - R1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Dubey, B. Imthurn, and E. K. Jackson 2-Methoxyestradiol: A Potential Treatment for Multiple Proliferative Disorders Endocrinology, September 1, 2007; 148(9): 4125 - 4127. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Straub The Complex Role of Estrogens in Inflammation Endocr. Rev., August 1, 2007; 28(5): 521 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barton, M. R. Meyer, and E. Haas Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women: Does Aging Limit Therapeutic Benefits? Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1669 - 1672. [Full Text] [PDF]
|
|
|
|
|
|
A. Sherwood, J. K. Bower, J. McFetridge-Durdle, J. A. Blumenthal, L. K. Newby, and A. L. Hinderliter Age Moderates the Short-Term Effects of Transdermal 17{beta}-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1782 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Mann, D. J. Rowlands, F. Y.L. Li, P. de Winter, and R. C.M. Siow Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression Cardiovasc Res, July 15, 2007; 75(2): 261 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yuan and J. Xu Loss-of-Function Deletion of the Steroid Receptor Coactivator-1 Gene in Mice Reduces Estrogen Effect on the Vascular Injury Response Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1521 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Traupe, C. D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, and M. Barton Distinct Roles of Estrogen Receptors {alpha} and {beta} Mediating Acute Vasodilation of Epicardial Coronary Arteries Hypertension, June 1, 2007; 49(6): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bolego, E. Vegeto, C. Pinna, A. Maggi, and A. Cignarella Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2192 - 2199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Lambrinoudaki, G. Christodoulakos, D. Rizos, E. Economou, J. Argeitis, S. Vlachou, M. Creatsa, E. Kouskouni, and D. Botsis Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur. J. Endocrinol., June 1, 2006; 154(6): 907 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Meyer, E. Haas, and M. Barton Gender Differences of Cardiovascular Disease: New Perspectives for Estrogen Receptor Signaling Hypertension, June 1, 2006; 47(6): 1019 - 1026. [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Cruz, L. Luksha, H. Logman, L. Poston, S. Agewall, and K. Kublickiene Acute responses to phytoestrogens in small arteries from men with coronary heart disease Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1969 - H1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Piper and E. A. Martinson Cardiovascular Research speeds up-Even more Cardiovasc Res, March 1, 2006; 69(4): 773 - 776. [Full Text] [PDF]
|
|
|
|
|
|
S. Pepe and E. G. Lakatta Aging hearts and vessels: Masters of adaptation and survival Cardiovasc Res, May 1, 2005; 66(2): 190 - 193. [Full Text] [PDF]
|
|